Literature DB >> 15087111

Novel mutations in three patients with LGMD2C with phenotypic differences.

Sascha Vermeer1, Aad Verrips, Michèl A A P Willemsen, Henk J ter Laak, Ieke B Ginjaar, Ben C J Hamel.   

Abstract

Limb-girdle muscular dystrophy type 2C is an autosomal-recessive disorder caused by mutations in gamma-sarcoglycan encoding gene. This disease is characterized by childhood onset of progressive muscular dystrophy. Because of the clinical presentation, this disorder may be misdiagnosed as a dystrophinopathy. Two males (Patients A and B) from one Turkish family and one male (Patient C) from a Moroccan family had progressive walking disturbances for several years, exercise intolerance, and leg pains. Clinical examination revealed limb-girdle weakness and calf hypertrophy. Serum creatine kinase levels ranged from 1100 to 19000 U/L. The initial findings and course of the disease were less severe in Patient B compared with his brother (Patient A) at the same age. By means of immunohistochemistry on muscle biopsy all patients manifested reduced expression of alpha-, beta-, gamma-, and delta-sarcoglycans. DNA sequence analysis revealed a homozygous splice site mutation in exon 5 (IVS5+2T>C) in the Turkish family. In the patient from the Moroccan family a homozygous nonsense mutation in exon 2 (93G>A;Trp31X) was present. In conclusion, this report describes the clinical, histologic, and immunohistochemical characteristics of three children with limb-girdle muscular dystrophy type 2C. Two novel mutations in the gamma-sarcoglycan gene were present. We found phenotypic differences in two brothers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15087111     DOI: 10.1016/j.pediatrneurol.2003.11.006

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  3 in total

Review 1.  Genomics and genetics in the biology of adaptation to exercise.

Authors:  Claude Bouchard; Tuomo Rankinen; James A Timmons
Journal:  Compr Physiol       Date:  2011-07       Impact factor: 9.090

2.  Phenotypic and immunohistochemical characterization of sarcoglycanopathies.

Authors:  Ana F B Ferreira; Mary S Carvalho; Maria Bernadete D Resende; Alda Wakamatsu; Umbertina Conti Reed; Suely Kazue Nagahashi Marie
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

3.  Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice.

Authors:  Justin M Percival; Kendra N E Anderson; Paul Gregorevic; Jeffrey S Chamberlain; Stanley C Froehner
Journal:  PLoS One       Date:  2008-10-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.